Karyopharm Therapeutics Inc (KPTI)

9.28
NASDAQ : Health Care
Prev Close 9.03
Day Low/High 8.91 / 9.46
52 Wk Low/High 4.83 / 17.12
Avg Volume 349.50K
Exchange NASDAQ
Shares Outstanding 41.24M
Market Cap 372.43M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm To Ring The Nasdaq Stock Market Closing Bell

Karyopharm To Ring The Nasdaq Stock Market Closing Bell

Celebration Commemorating the Company's 8th Anniversary

Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016

Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016

Conference Call Scheduled for Monday, November 7, 2016 at 5:00 p.m. ET

Karyopharm Therapeutics is Now Oversold (KPTI)

Karyopharm Therapeutics is Now Oversold (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc shares, but tentative about paying the going market price of $8.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $7.50 strike, which has a bid at the time of this writing of 80 cents.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Markets Very Sluggish as August Nears an End

Markets Very Sluggish as August Nears an End

Even concerns about a possible Fed rate hike do not appear to be affecting traders.

Noteworthy Monday Option Activity: KPTI, SHLD, MXWL

Noteworthy Monday Option Activity: KPTI, SHLD, MXWL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karyopharm Therapeutics Inc , where a total volume of 2,316 contracts has been traded thus far today, a contract volume which is representative of approximately 231,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 168.7% of KPTI's average daily trading volume over the past month, of 137,260 shares.

These 7 Stocks Under $10 Could Make You a Lot of Money

These 7 Stocks Under $10 Could Make You a Lot of Money

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016

Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016

Conference Call Scheduled for Thursday, August 4, 2016 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $7.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $5 strike, which has a bid at the time of this writing of 60 cents.

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

First-in-class Immunometabolic Modulator, PAK4/NAMPT Inhibitor, to be Evaluated in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.